Form 4: Director Daniella Beckman Receives Vor Biopharma Options

Director Daniella Beckman was granted 53,283 stock options in Vor Biopharma Inc. as part of a standard equity compensation plan.

Summary

• Director Daniella Beckman acquired 53,283 stock options in Vor Biopharma Inc. (VOR).
• The options have an exercise price of $14.09 per share.
• The grant date for the transaction was June 11, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of VOR common stock.

Future Outlook

The options vest monthly over a 36-month period, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent, though they remain subject to standard vesting schedules.

Comparison to Industry Standards

• The 36-month vesting schedule is consistent with standard corporate governance practices for board-level equity compensation in the biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of options on July 11, 2026.

Key Dates

Keywords

Vor Biopharma, VOR, Form 4, Insider Trading, Stock Options, Director Compensation